2016
Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization
Man S, Cox M, Patel P, Smith E, Reeves M, Saver J, Bhatt D, Xian Y, Schwamm L, Fonarow G. Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization. Stroke 2016, 48: 412-419. PMID: 28008094, DOI: 10.1161/strokeaha.116.014426.Peer-Reviewed Original ResearchConceptsHealthcare Facilities Accreditation ProgramPSC certificationStroke patientsJoint CommissionIntravenous tissue-type plasminogen activator useHospital risk-adjusted mortalityAcute ischemic stroke patientsStroke qualityAcute ischemic stroke admissionsCare qualityPrimary stroke center certificationGuidelines-Stroke hospitalsStroke center certificationIschemic stroke patientsIschemic stroke admissionsRisk-adjusted mortalityEvidence-based careSystems of careAccreditation programGuidelines-StrokeHospital outcomesNeedle timeStroke admissionsCenter certificationGroup of hospitals
2014
Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative
Fonarow G, Zhao X, Smith E, Saver J, Reeves M, Bhatt D, Xian Y, Hernandez A, Peterson E, Schwamm L. Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. JAMA 2014, 311: 1632-1640. PMID: 24756513, DOI: 10.1001/jama.2014.3203.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrain IschemiaDecision Support Systems, ClinicalFemaleFibrinolytic AgentsGuideline AdherenceHospital MortalityHospitalsHumansIntracranial HemorrhagesMaleMiddle AgedPatient DischargeQuality ImprovementRegistriesStrokeThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsAcute ischemic strokeQuality improvement initiativesTissue plasminogen activatorNational quality improvement initiativeSymptomatic intracranial hemorrhageDTN timeTPA administrationIntracranial hemorrhagePostintervention periodIschemic strokeNeedle timeClinical outcomesPreintervention periodImprovement initiativesHospital risk-adjusted mortalityIntravenous tissue plasminogen activatorTissue plasminogen activator administrationMedian DTN timePercentage of patientsProportion of patientsClinical decision support toolRisk-adjusted mortalityGuidelines-StrokeHospital mortalityYear preintervention